Everolimus for the second-line treatment of advanced and/or metastatic renal cell cancer: a critique of the submission from Novartis
- Resource Type
- article
- Source
- Health Technology Assessment, Vol 14, Iss Suppl 2 (2010)
- Subject
Medical technology R855-855.5 - Language
- English
- ISSN
- 1366-5278
2046-4924